321 related articles for article (PubMed ID: 28364288)
1. Co-administration of proton pump inhibitors ameliorates nephrotoxicity in patients receiving chemotherapy with cisplatin and fluorouracil: a retrospective cohort study.
Ikemura K; Oshima K; Enokiya T; Okamoto A; Oda H; Mizuno T; Ishinaga H; Muraki Y; Iwamoto T; Takeuchi K; Katayama N; Okuda M
Cancer Chemother Pharmacol; 2017 May; 79(5):943-949. PubMed ID: 28364288
[TBL] [Abstract][Full Text] [Related]
2. Possible protective effect of pantoprazole against cisplatin-induced nephrotoxicity in head and neck cancer patients: a randomized controlled trial.
Ghonaim E; El-Haggar S; Gohar S
Med Oncol; 2021 Aug; 38(9):108. PubMed ID: 34357466
[TBL] [Abstract][Full Text] [Related]
3. Randomized controlled phase II comparison study of concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil versus CCRT with cisplatin, 5-fluorouracil, methotrexate and leucovorin in patients with locally advanced squamous cell carcinoma of the head and neck.
Tsukuda M; Ishitoya J; Matsuda H; Horiuchi C; Taguchi T; Takahashi M; Nishimura G; Kawakami M; Watanabe M; Niho T; Kawano T; Ikeda Y; Sakuma Y; Shiono O; Komatsu M
Cancer Chemother Pharmacol; 2010 Sep; 66(4):729-36. PubMed ID: 20033810
[TBL] [Abstract][Full Text] [Related]
4. [Measurement of creatinine clearance and urinary NAG for the evaluation of cis-platinum induced nephrotoxicity].
Kubota A; Yoshida T; Tsukuda M; Furukawa S; Miyata K; Mochimatsu I; Sawaki S
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2599-605. PubMed ID: 2774590
[TBL] [Abstract][Full Text] [Related]
5. Magnesium co-administration decreases cisplatin-induced nephrotoxicity in the multiple cisplatin administration.
Saito Y; Okamoto K; Kobayashi M; Narumi K; Furugen A; Yamada T; Iseki K
Life Sci; 2017 Nov; 189():18-22. PubMed ID: 28864226
[TBL] [Abstract][Full Text] [Related]
6. Long-term administration of low-dose cisplatin plus 5-fluorouracil prolongs the postoperative survival of patients with esophageal cancer.
Shiozaki A; Yamagishi H; Itoi H; Fujiwara H; Kikuchi S; Okamoto K; Ichikawa D; Fuji N; Ochiai T; Sonoyama T; Ueda Y
Oncol Rep; 2005 Apr; 13(4):667-72. PubMed ID: 15756440
[TBL] [Abstract][Full Text] [Related]
7. Lower blood pressure and risk of cisplatin nephrotoxicity: a retrospective cohort study.
Komaki K; Kusaba T; Tanaka M; Kado H; Shiotsu Y; Matsui M; Shiozaki A; Nakano H; Ishikawa T; Fujiwara H; Konishi H; Itoh Y; Matoba S; Tamagaki K
BMC Cancer; 2017 Feb; 17(1):144. PubMed ID: 28219368
[TBL] [Abstract][Full Text] [Related]
8. [Low-dose CDDP and 5-FU for head and neck cancer patients].
Fujii M; Kanke M; Tomita T
Gan To Kagaku Ryoho; 1999 Oct; 26(11):1542-7. PubMed ID: 10553410
[TBL] [Abstract][Full Text] [Related]
9. Risk Factors for Cisplatin-Induced Nephrotoxicity: A Multicenter Retrospective Study.
Miyoshi T; Uoi M; Omura F; Tsumagari K; Maesaki S; Yokota C
Oncology; 2021; 99(2):105-113. PubMed ID: 32966986
[TBL] [Abstract][Full Text] [Related]
10. Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer.
De Andrés L; Brunet J; López-Pousa A; Burgués J; Vega M; Tabernero JM; Mesía R; López JJ
J Clin Oncol; 1995 Jun; 13(6):1493-500. PubMed ID: 7751897
[TBL] [Abstract][Full Text] [Related]
11. Absence of effect of SLC22A2 genotype on cisplatin-induced nephrotoxicity in oesophageal cancer patients receiving cisplatin and 5-fluorouracil: report of results discordant with those of earlier studies.
Hinai Y; Motoyama S; Niioka T; Miura M
J Clin Pharm Ther; 2013 Dec; 38(6):498-503. PubMed ID: 24102360
[TBL] [Abstract][Full Text] [Related]
12. Sequence-dependence of cisplatin and 5-fluorouracil in advanced and recurrent gastric cancer.
Koizumi W; Kurihara M; Hasegawa K; Chonan A; Kubo Y; Maekawa R; Iwasaki R; Sasai T; Fukuyama Y; Ishikawa K; Miyoshi K; Yasutake K; Hayakawa M
Oncol Rep; 2004 Sep; 12(3):557-61. PubMed ID: 15289837
[TBL] [Abstract][Full Text] [Related]
13. Weekly 5-fluorouracil and folinic acid plus escalating doses of cisplatin with glutathione protection in patients with advanced head and neck cancer.
Gebbia V; Valenza R; Testa A; Zerillo G; Restivo S; Cupido G; Ingria F; Spadafora G; Barbaccia C; Cannata G
Med Oncol Tumor Pharmacother; 1992; 9(4):165-8. PubMed ID: 1342059
[TBL] [Abstract][Full Text] [Related]
14. A randomized trial between two neoadjuvant chemotherapy protocols: CDDP + 5-FU versus CDDP + VP16 in advanced cancer of the head and neck.
Prévost A; Mérol JC; Aimé P; Moutel K; Roger-Liautaud F; Nasca S; Legros M; Coninx P
Oncol Rep; 2005 Sep; 14(3):771-6. PubMed ID: 16077990
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of paclitaxel, cisplatin, and fluorouracil (TCF) for advanced gastric cancer.
Hara T; Omura K; Hirano M; Asada Y; Munemoto Y; Sakamoto J
Cancer Chemother Pharmacol; 2007 Apr; 59(5):631-6. PubMed ID: 16924496
[TBL] [Abstract][Full Text] [Related]
16. [Change of creatinine clearance rate in accordance with aging in Japanese patients with head and neck cancer].
Nishimura G; Horiuchi C; Yoshida T; Kawakami M; Yabuki K; Taguchi T; Nagao J; Kondo N; Masuda Y; Matsuda H; Mikami Y; Tsukuda M
Gan To Kagaku Ryoho; 2006 Apr; 33(4):463-6. PubMed ID: 16612154
[TBL] [Abstract][Full Text] [Related]
17. [Combination chemotherapy with 5-FU and CDDP or CDDP analog for head and neck cancer].
Fujii M; Ohno Y; Tokumaru Y; Imanishi Y; Kanke M
Gan To Kagaku Ryoho; 1996 Nov; 23(13):1740-6. PubMed ID: 8937483
[TBL] [Abstract][Full Text] [Related]
18. Hydration regimen and hematological toxicity of a cisplatin-based chemotherapy regimen. Clinical observations and pharmacokinetic analysis.
Numico G; Benasso M; Vannozzi MO; Merlano M; Rosso R; Viale M; Esposito M
Anticancer Res; 1998; 18(2B):1313-8. PubMed ID: 9615808
[TBL] [Abstract][Full Text] [Related]
19. Radiation therapy combined with cis-diammine-glycolatoplatinum (nedaplatin) and 5-fluorouracil for Japanese stage II-IV esophageal cancer compared with cisplatin plus 5-fluorouracil regimen: a retrospective study.
Yamashita H; Nakagawa K; Tago M; Igaki H; Nakamura N; Shiraishi K; Sasano N; Ohtomo K
Dis Esophagus; 2006; 19(1):15-9. PubMed ID: 16364038
[TBL] [Abstract][Full Text] [Related]
20. Premedication with intravenous magnesium has a protective effect against cisplatin-induced nephrotoxicity.
Saito Y; Kobayashi M; Yamada T; Kasashi K; Honma R; Takeuchi S; Shimizu Y; Kinoshita I; Dosaka-Akita H; Iseki K
Support Care Cancer; 2017 Feb; 25(2):481-487. PubMed ID: 27699503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
